Author

Bryan Latrell Holloman

Baylor College of MedicineORCID 0000-0002-9891-9001Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Checo J. RorieiD· 1 shared Dipongkor SahaiD· 1 shared Dong LuiD· 1 shared Feng JiniD· 1 shared Hanfeng LiniD· 1 shared Howard L. KaufmaniD· 1 shared Jin WangiD· 1 shared Joseph L. GravesiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Checo J. RorieORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors

Md. Iftehimul, Robert Howard Newman, Scott Henry Harrison, Roshonda B. Jones, Perpetua M. Muganda, Bryan Latrell Holloman, Muhammad T. Hossain, Checo J. Rorie, Misty D. Thomas, Joseph L. Graves, Howard L. Kaufman, Dipongkor Saha

This study tracks T cell transcriptional changes in 4T1 tumors over time, revealing functional decline, reduced TCR diversity, and immunosuppressive shifts in the tumor microenvironment.

bioRxiv · Oct 17, 2025 · PreprintCancer Biology

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity

Xin Yu, Dong Lu, Xiaoli Qi, Rishi R. Paudel, Hanfeng Lin, Bryan Latrell Holloman, Feng Jin, Longyong Xu, Lang Ding, Weiyi Peng, Meng Carla Wang, Xi Chen, Jin Wang

This paper develops a first-in-class RIPK1 degrader, LD4172, which enhances antitumor immunity by promoting immunogenic cell death and sensitizing tumors to anti-PD1 therapy.

Nature Communications · Dec 16, 2024Peer-reviewedPharmacology & Toxicology